Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $57.80 Consensus PT from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have earned a consensus recommendation of "Buy" from the nine research firms that are presently covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $53.50.

A number of brokerages have recently commented on ARCT. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a report on Monday, March 10th. Wells Fargo & Company lowered their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Scotiabank started coverage on shares of Arcturus Therapeutics in a research report on Wednesday. They issued a "sector outperform" rating and a $32.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research report on Thursday, April 10th.

Arcturus Therapeutics Stock Up 3.0%

Shares of NASDAQ ARCT traded up $0.35 during midday trading on Friday, hitting $12.17. The company had a trading volume of 45,264 shares, compared to its average volume of 446,318. Arcturus Therapeutics has a twelve month low of $8.04 and a twelve month high of $45.00. The business has a 50-day simple moving average of $11.31 and a two-hundred day simple moving average of $14.88. The firm has a market capitalization of $330.17 million, a price-to-earnings ratio of -5.48 and a beta of 2.36.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $1.06. The firm had revenue of $29.38 million during the quarter, compared to the consensus estimate of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. On average, equities analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently modified their holdings of ARCT. Byrne Asset Management LLC lifted its holdings in Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 1,365 shares during the period. US Bancorp DE lifted its holdings in Arcturus Therapeutics by 218.9% in the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 2,329 shares during the period. Virtus ETF Advisers LLC lifted its holdings in Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 1,132 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Arcturus Therapeutics in the fourth quarter worth about $71,000. Finally, Strs Ohio acquired a new stake in Arcturus Therapeutics in the first quarter worth about $89,000. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.